[Skip to Content]
[Skip to Content Landing]
Views 1,039
Citations 0
Research Letter
September 4, 2019

Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

Author Affiliations
  • 1Service de Dermatologie et d’Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France
  • 2Sorbonne Universités, Paris, Centre d’Immunologie et des Maladies Infectieuses–Paris (Cimi-Paris), INSERM U1135, Paris, France
  • 3Service de Dermatologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
  • 4Service de Dermatologie, Hôpital Saint André, Centre de Référence des Maladies Rares de la Peau, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  • 5Service de Dermatologie, Hôpital Saint-Louis, Paris, France
  • 6Centre Hospitalier Universitaire de Lille, Service de Dermatologie et Vénérologie, F-59000 Lille, France,
  • 7University of Lille, INSERM U995-LIRIC-Lille Inflammation Research International Center, F-59000 Lille, France
  • 8Centre Hospitalier Universitaire de Nantes, Service de Dermatologie, Nantes, France
JAMA Dermatol. Published online September 4, 2019. doi:10.1001/jamadermatol.2019.2613

The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 Injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher in the dupilumab groups than in the placebo groups in pivotal studies.1,2 A recent study by Zhu et al3 reported new regional dermatoses in 17 patients with AD treated with dupilumab, with facial area involvement in 14 cases, whereas Blauvelt et al4 reported an equal improvement of AD with dupilumab on different anatomic regions in a post hoc analysis of data extracted from 4 phase 3 clinical trials.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words